Abstract:Objective:To evaluate short-term efficacy and safety of fluticasone propionate 0.05% cream alone or in combination with calcipotriol 0.005% ointment in the treatment of mild to moderate plaque psoriasis.Methods:From October 2020 to January 2021, a randomized, open-labeled, self-controlled clinical trial was conducted among 30 patients with mild to moderate plaque psoriasis in Beijing Friendship Hospital. Skin lesions on the extremity of one side were topically treated with calcipotriol 0.005% ointment in the morning and fluticasone propionate 0.05% cream in the evening (combination group) , and lesions on the contralateral extremity were topically treated with fluticasone propionate 0.05% cream twice a day (fluticasone propionate group) . The treatment lasted 4 weeks. Before and 1, 2, 4 weeks after the start of treatment, the patients were followed up, clinical indices including static physician′s global assessment (sPGA) and psoriasis area and severity index (PASI) were evaluated, and adverse events were recorded. Efficacy and safety were evaluated by using repeated measures analysis of variance, multivariate analysis of variance, Mann-Whitney rank sum test and two-independent-sample t test. Results:Before the treatment, there was no significant difference in sPGA or PASI score between the combination group and fluticasone propionate group (both P > 0.05) . After 1-week treatment, the fluticasone propionate group showed significantly decreased sPGA (1.10 ± 0.31 points) and PASI scores (1.05 ± 0.51 points) compared with the combination group (1.73 ± 0.45 points, 1.38 ± 0.69 points, F= 40.74, 4.38, respectively, both P < 0.05) ; after 2- and 4-week treatment, the combination group showed significantly decreased sPGA (0.83 ± 0.46 points, 0.23 ± 0.43 points, respectively) and PASI scores (0.53 ± 0.47 points, 0.23 ± 0.50 points, respectively) compared with the fluticasone propionate group (sPGA: 1.03 ± 0.18 points, 0.97 ± 0.32 points, F= 4.88, 56.14, respectively, both P < 0.05; PASI: 1.03 ± 0.51 points, 0.92 ± 0.54 points, F= 15.20, 26.36, respectively, both P < 0.05) . After 1-week treatment, the infiltration/hypertrophy severity score was significantly lower in the fluticasone propionate group than in the combination group ( U= 165.00, P < 0.05) ; after 2- and 4-week treatment, the erythema and scaling severity scores were significantly lower in the combination group than in the fluticasone propionate group (erythema: U= 540.00, 765.00, respectively, both P < 0.05; scaling: U= 825.00, 795.00, respectively, both P < 0.05) . Conclusion:Fluticasone propionate 0.05% cream alone exhibited a rapid onset of efficacy in the treatment of psoriasis, while fluticasone propionate 0.05% cream combined with calcipotriol 0.005% ointment was more effective after 2- and 4-week treatment, and both regimens showed a favorable safety profile.

Efficacy and cost: topical treatment versus topical treatment combined with NB-UVB for mild plaque psoriasis

Topical Treatment of All-Trans Retinoic Acid Cream Combined with Penciclovir Cream for Verruca Plana: A Multiple Centre,double-Blind and Control Study

Efficacy, Safety, and Cost-Effectiveness of All-Trans Retinoic Acid/clobetasol Propionate Compound Ointment in the Treatment of Mild to Moderate Psoriasis Vulgaris: A Randomized, Single-Blind, Multicenter Clinical Trial.

Narrow band ultraviolet monotherapy for severe psoriasis

Effect of NB-UVB irradiation in combination with a small dose of acitretin and tazarotene 0. 05% gel on severe plaque psoriasis

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Efficacy of Fluticasone Propionate Cream Alone or in Combination with Calcipotriol Ointment in the Treatment of Mild to Moderate Plaque Psoriasis: a Randomized Self-Controlled Study

Comparative effectiveness of combined biologic agents versus standard therapies in the treatment of plaque psoriasis: a retrospective analysis

Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.

Efficacy And Safety Of Ustekinumab In Chinese Patients With Moderate To Severe Plaque-Type Psoriasis: Results From A Phase 3 Clinical Trial (Lotus)

Effect of Traditional Chinese Medicine plus narrow-band medium-wave ultraviolet B radiation on moderate-to-severe psoriasis vulgaris in a case series

Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials

Recombinant Human Tumor Necrosis Factor Receptor Type Ⅱ - IgG Fc Fusion Protein for the Treatment of Moderate to Severe Psoriasis Vulgaris:A Multicenter, Randomized, Parallel-Group, Controlled Clinical Trial

Comparison of Safety and Efficacy Between Calcipotriol Plus Betamethasone Dipropionate Gel and Calcipotriol Scalp Solution As Long-Term Treatment for Scalp Psoriasis in Chinese Patients: a National, Multicentre, Prospective, Randomized, Active-Controlled Phase 4 Trial

Narrow-band Ultraviolet B and Conventional UVB Phototherapy in Psoriasis: a Randomised Controlled Trial

Observation of the therapeutic efficacy of acitretin combined with narrow-band ultraviolet

Ramdomized Double-Blind Parallel Comparitive Study of 8-Methoxypsoralen in the Treatment of Plaque Psoriasis Vulgaris

Asian Consensus on Assessment and Management of Mild to Moderate Plaque Psoriasis with Topical Therapy.

Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Calcipotriol Scalp Solution In The Treatment Of Scalp Psoriasis: A Randomized, Controlled Trial Investigating Efficacy And Safety In A Chinese Population

Efficacy of Tazarotene 0.05%/betamethasone Dipropionate 0.05% Cream in the Treatment of Mild to Moderate Psoriasis Vulgaris: a Multicenter Clinical Observational Study

Clinical study of narrowbard ultraviolet B phototherapy with herb steam in the treatment of psorisasis vulgaris